Monogram Technologies Reports First Quarter 2025 Financial Results

Core Insights - Monogram Technologies Inc. has received FDA clearance for its mBôs™ Total Knee Arthroplasty (TKA) System, marking a significant milestone for the company and its technology [4][9] - The company is set to conduct a groundbreaking clinical trial for autonomous saw-based robotic TKA surgeries on live patients, which is expected to demonstrate the potential of robotic precision in surgical procedures [5][9] - Monogram is preparing for initial placements of the mBôs system with key opinion leader surgeons in the U.S. and advancing patient enrollment for the clinical trial in India [6][10] Financial Performance - Research and development expenses decreased by 6% to $2.3 million in Q1 2025, compared to $2.4 million in the same quarter of the previous year [11] - Marketing and advertising expenses saw a significant decrease of 63%, dropping to $44,000 from $120,000 year-over-year [12] - General and administrative expenses were $1.0 million, slightly down from $1.1 million in the prior-year quarter, with a net loss of $3.2 million for Q1 2025, an improvement from a net loss of $3.5 million in Q1 2024 [13] Cash Position - As of March 31, 2025, cash and cash equivalents totaled $13.3 million, down from $15.7 million at the end of 2024, indicating a focus on capital efficiency in commercialization efforts [14] Upcoming Initiatives - The company plans to initiate patient enrollment for the clinical trial and begin the first live patient surgeries in India within 90 business days [9][10] - Monogram is also exploring additional domestic and international partnerships to support the commercialization of the mBôs TKA System [7][10]